# US 2024/0424073 A1 · Contraceptive vaccine based on the sperm-associated protein catsper

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0424073 A1
- Document ID: US20240424073A1
- Status: Published application
- Kind: A1
- Application number: 18/437,608
- Filed: 2024-02-09
- Published: 2024-12-26
- Earliest claimed: 2019-02-08
- Assignees: Rensselaer Polytechnic Institute
- Applicants: Rensselaer Polytechnic Institute
- Inventors: Christopher BYSTROFF; Jean-Ju Lucia CHUNG
- Web page: https://patentgrep.com/patent/US20240424073A1

## CPC

- A61K 39/0006: {Contraceptive vaccins; Vaccines against sex hormones}
- A61P 15/16: Masculine contraceptives
- A61P 15/18: Feminine contraceptives
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/6075: {Viral proteins}
- C12N 2710/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2710/20023: Virus like particles [VLP]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A composition includes a contraceptive chimeric virus-like particle with an antigenic carrier domain and one or more antigenic regions from a sperm cell in the antigenic carrier domain, with the antigenic carrier domain including human papillomavirus L1 capsid protein and the antigenic regions including one or more structural elements of the Catsper ion channel complex. When administered to a patient, the contraceptive vaccine stimulates production of anti-sperm antibodies that, upon binding to a sperm cell, inhibit the sperm cell's motility and thus inhibit the ability of the sperm cell to fertilize an egg cell. The induced immunoinfertility of the composition can be reversed for brief or extended lengths of time by overdosing the patient with a reversal agent lacking the antigenic carrier domain but having a protein sequence substantially identical to that of the one or more antigenic regions to sequester the anti-sperm antibodies.

## Claims

### Claim 1

A contraceptive chimeric virus-like particle, comprising:
an antigenic carrier domain; and
one or more antigenic regions from a sperm cell in the antigenic carrier domain.

### Claim 2 (depends on 1)

The chimeric virus-like particle according to claim 1, wherein the antigenic carrier domain includes one or more capsid proteins.

### Claim 3 (depends on 2)

The chimeric virus-like particle according to claim 2, wherein the one or more capsid proteins include L1 from human papillomavirus.

### Claim 4 (depends on 1)

The chimeric virus-like particle according to claim 1, wherein CGP amino acid residues are adjacent the N-terminal end of the one or more antigenic regions and GPC amino acid residues are adjacent the C-terminal end of the one or more antigenic regions.

### Claim 5 (depends on 1)

The chimeric virus-like particle according to claim 1, wherein the one or more antigenic regions include structural elements of the Catsper ion channel complex.

### Claim 6 (depends on 5)

The chimeric virus-like particle according to claim 5, wherein the structural elements include at least a portion of one or more loops positioned between the transmembrane helical segments of the Catsper ion channel complex.

### Claim 7 (depends on 6)

The chimeric virus-like particle according to claim 6, wherein the structural elements include at least a portion of: the loop between Catsper1 s1 and Catsper1 s2, the loop between Catsper2 s5 and Catsper2 p-loop, the loop between Catsper1 s3 and Catsper1 s4, the loop between Catsper2 s1 and Catsper2 s2, the loop between Catsper3 s1 and Catsper3 s2, the loop between Catsper1 s5 and Catsper1 p-loop, the loop between Catsper2 p-loop and Catsper2 s6, the loop between Catsper3 s3 and Catsper3 s4, the loop between Catsper3 s5 and Catsper3 p-loop, the loop between Catsper3 p-loop and Catsper3 s6, the loop between Catsper4 s1 and Catsper4 s2, the loop between Catsper4 p-loop and Catsper4 s6, Catsperδ loop 785-805, Catsperε loop 331-348, or combinations thereof.

### Claim 8 (depends on 7)

The chimeric virus-like particle according to claim 7, wherein the virus-like particle includes SEQ. ID. NO.: 1, SEQ. ID. NO.: 2, SEQ. ID. NO.: 3, SEQ. ID. NO.: 4, SEQ. ID. NO.: 5, SEQ. ID. NO.: 6, SEQ. ID. NO.: 7, or combinations thereof.

### Claim 9

A method of making a contraceptive chimeric virus-like particle, comprising:
inserting a gene for an antigenic carrier protein into a plasmid;
preparing overlapping primers for a chimeric gene of the antigenic carrier and one or more antigenic regions from a sperm cell;
performing a polymerase chain reaction to amplify the chimeric gene; and
synthesizing a virus-like particle from the chimeric gene.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the one or more antigenic regions include structural elements of the Catsper ion channel complex.

### Claim 11 (depends on 10)

The method according to claim 10, wherein the structural elements include at least a portion of one or more loops positioned between the transmembrane helical segments of the Catsper ion channel complex.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the structural elements include at least a portion of: the loop between Catsper1 s1 and Catsper1 s2, the loop between Catsper2 s5 and Catsper2 p-loop, the loop between Catsper1 s3 and Catsper1 s4, the loop between Catsper2 s1 and Catsper2 s2, the loop between Catsper3 s1 and Catsper3 s2, the loop between Catsper1 s5 and Catsper1 p-loop, the loop between Catsper2 p-loop and Catsper2 s6, the loop between Catsper3 s3 and Catsper3 s4, the loop between Catsper3 s5 and Catsper3 p-loop, the loop between Catsper3 p-loop and Catsper3 s6, the loop between Catsper4 s1 and Catsper4 s2, the loop between Catsper4 p-loop and Catsper4 s6, Catsperδ loop 785-805, Catsperε loop 331-348, or combinations thereof.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the virus-like particle includes SEQ. ID. NO.: 1, SEQ. ID. NO.: 2, SEQ. ID. NO.: 3, SEQ. ID. NO.: 4, SEQ. ID. NO.: 5, SEQ. ID. NO.: 6, SEQ. ID. NO.: 7, or combinations thereof.

### Claim 14

A method for providing contraceptive treatment to a patient, comprising:
preparing a composition including a contraceptive chimeric virus-like particle including an antigenic carrier domain and one or more antigenic regions from a sperm cell in the antigenic carrier domain; and
administering the composition to a patient to heighten an immune response of the patient to the one or more antigenic regions.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the antigenic carrier domain includes L1 from human papillomavirus.

### Claim 16 (depends on 14)

The method according to claim 14, wherein the one or more antigenic regions include structural elements of the Catsper ion channel complex, wherein the structural elements include at least a portion of: the loop between Catsper1 s1 and Catsper1 s2, the loop between Catsper2 s5 and Catsper2 p-loop, the loop between Catsper1 s3 and Catsper1 s4, the loop between Catsper2 s1 and Catsper2 s2, the loop between Catsper3 s1 and Catsper3 s2, the loop between Catsper1 s5 and Catsper1 p-loop, the loop between Catsper2 p-loop and Catsper2 s6, the loop between Catsper3 s3 and Catsper3 s4, the loop between Catsper3 s5 and Catsper3 p-loop, the loop between Catsper3 p-loop and Catsper3 s6, the loop between Catsper4 s1 and Catsper4 s2, the loop between Catsper4 p-loop and Catsper4 s6, Catsperδ loop 785-805, Catsperε loop 331-348, or combinations thereof.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the one or more antigenic regions includes SEQ. ID. NO.: 8, SEQ. ID. NO.: 9, SEQ. ID. NO.: 10, SEQ. ID. NO.: 11, SEQ. ID. NO.: 12, SEQ. ID. NO.: 13, SEQ. ID. NO.: 14, SEQ. ID. NO.: 15, SEQ. ID. NO.: 16, SEQ. ID. NO.: 17, SEQ. ID. NO.: 18, SEQ. ID. NO.: 19, SEQ. ID. NO.: 20, SEQ. ID. NO.: 21, SEQ. ID. NO.: 22, or combinations thereof.

### Claim 18 (depends on 14)

The method according to claim 14, wherein the composition is administered subcutaneously, intravenously, intranasally, or combinations thereof.

### Claim 19 (depends on 14)

The method according to claim 14, further comprising:
administering a supplemental composition to the patient to reverse the effects of the composition, the supplemental composition including a reversal agent having a protein sequence substantially identical to that of the one or more antigenic regions.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the reversal agent includes one or more peptides, the one or more peptides include SEQ. ID. NO.: 8, SEQ. ID. NO.: 9, SEQ. ID. NO.: 10, SEQ. ID. NO.: 11, SEQ. ID. NO.: 12, SEQ. ID. NO.: 13, SEQ. ID. NO.: 14, SEQ. ID. NO.: 15, SEQ. ID. NO.: 16, SEQ. ID. NO.: 17, SEQ. ID. NO.: 18, SEQ. ID. NO.: 19, SEQ. ID. NO.: 20, SEQ. ID. NO.: 21, SEQ. ID. NO.: 22, or combinations thereof.
